Cellistic completed the acquisition of Manufacturing Business Unit of Celyad Oncology from Celyad Oncology SA.
Cellistic emtered into asset purchase agreement to acquire Manufacturing Business Unit of Celyad Oncology from Celyad Oncology SA (ENXTBR:CYAD) for 6 million on September 20, 2022. The transaction is subject to a number of customary conditions and is anticipated to close in the fourth quarter of this year. Pierre-Olivier Mahieu and Sophie Rutten of Allen & Overy LLP (Brussels) acted as legal advisor to Celyad Oncology SA (ENXTBR:CYAD).
Cellistic completed the acquisition of Manufacturing Business Unit of Celyad Oncology from Celyad Oncology SA (ENXTBR:CYAD) in September 2022.